Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.

Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review

Open access
Maurice Dror, Corinne, Chi, Kim N., Khalaf, Daniel J. · 2021 · Translational Andrology and Urology

Abstract

Over the last two decades, there has been significant progress in the treatment of metastatic prostate cancer. Multiple treatments with diverse mechanisms of action have improved clinical outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) including taxane chemotherapy, immunotherapy, potent androgen receptor pathway inhibitors (ARPI), and radiopharmaceuticals (radium-223). As these treatments have entered standard clinical practise, clinicians have been challenged on how to optimally select and sequence them as the landmark studies establishing their efficacy had control arms with placebo or minimally effective therapy and there is a paucity of prospective trials examining treatment sequencing. More recently, the situation has been further complicated as the earlier up-front use of docetaxel and ARPI with standard gonadal testosterone inhibition has been shown to impart substantial improvements in disease control and survival for patients with castration sensitive prostate cancer. As new therapies enter into clinical practise such as the inhibitors of Poly (ADP-Ribose) Polymerase and Prostate Specific Membrane Antigen (PSMA)-targeted therapy, how to optimally select and sequence available treatments will be a continued dilemma in the absence of validated predictive biomarkers. This review will summarize the literature supporting the use of each active agent in mCRPC. We will propose a framework which will guide the selection of appropriate agents based on prior therapies, disease characteristics and biomarkers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21037/tau-20-1341

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 84 references

Research works printed but not linked: 2

  1. [35]Khalaf DJ Annala M Taavitsainen S Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol 2019; 20: 1730- 9. 10.1016/S1470-2045(19)30688-6 31727538 · DOI · Paper page
  2. [49]Beer TM Armstrong AJ Rathkopf D Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol 2017; 71: 151- 4. 10.1016/j.eururo.2016.07.032 27477525 PMC5570461 · DOI · Paper page

Cited by

See all 14

Metadata

Authors
Maurice Dror, C., Chi, K. N., & Khalaf, D. J.
Affiliations
BC Cancer Agency (CA)
Corresponding author
Khalaf, Daniel J.
Venue
Translational Andrology and Urology
Published
2021-10
Volume
10
Issue
10
Pages
3931-3945
ISSN
  • 2223-4683 (ISSN-L)
  • 2223-4691
OpenAlex
W3154460154
Cited by
14
References
84
Citations by year
2026: 1 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 1
FWCI
0.36
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Translational Andrology and Urology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Prostate Cancer Foundation
  • Pfizer
  • Sanofi
  • Astellas Pharma
  • Daiichi Sankyo Europe
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
metastatic castration-resistant prostate cancer, treatment sequencing, treatment selection, androgen receptor pathway inhibitors, docetaxel, radium-223, immunotherapy, taxane-based chemotherapy, PARP inhibitors, PSMA-targeted therapy, predictive biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review. https://app.cochat.ai/papers/10.21037/tau-20-1341
The paper
Maurice Dror, C., Chi, K. N., & Khalaf, D. J. (2021). Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review. Translational Andrology and Urology. https://doi.org/10.21037/tau-20-1341

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.